Compare TWST & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWST | DYN |
|---|---|---|
| Founded | 2013 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.9B |
| IPO Year | 2018 | 2020 |
| Metric | TWST | DYN |
|---|---|---|
| Price | $57.51 | $17.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $46.88 | $37.00 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $376,572,000.00 | N/A |
| Revenue This Year | $18.91 | N/A |
| Revenue Next Year | $15.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.32 | N/A |
| 52 Week Low | $23.30 | $8.25 |
| 52 Week High | $66.06 | $25.00 |
| Indicator | TWST | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 52.71 | 42.74 |
| Support Level | $41.85 | $16.47 |
| Resistance Level | $57.88 | $19.65 |
| Average True Range (ATR) | 3.41 | 0.86 |
| MACD | -0.62 | -0.26 |
| Stochastic Oscillator | 14.35 | 7.01 |
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.